Special Issue

Advances in Therapeutic Strategies for Gastrointestinal Diseases and Diabetes

Message from the Guest Editors

Diabetes and gastrointestinal diseases are interconnected through the complex interplay of metabolism, digestion, and systemic health. Diabetes medications can sometimes induce or worsen gastrointestinal issues, while drugs for gastrointestinal conditions may impact glucose metabolism, potentially contributing to the development or exacerbation of diabetes. Understanding these connections can help in better managing both diabetes and gastrointestinal diseases, emphasizing the importance of a holistic approach to treatment that considers the interplay between these conditions. Research topics may include, but are not limited to, the following:

Recent advancements in therapeutic strategies for diabetes.

Recent advancements in therapeutic strategies for gastrointestinal diseases.

Recent advancements in therapeutic strategies for gastrointestinal disorders in diabetes.

Impacts of diabetes medications on gastrointestinal health.

Impacts of gastrointestinal medications on diabetes management.

Guest Editors

Dr. Seungil Ro

1. Department of Physiology and Cell Biology, University of Nevada School of Medicine, Reno, NV 89557, USA 2. RosVivo Therapeutics, Applied Research Facility, 1664 N. Virginia St., Reno, NV 89557, USA

Dr. Seeun Ha

Department of Microbiology and Immunology, University of Nevada School of Medicine, Reno, NV 89557, USA

Deadline for manuscript submissions

closed (31 May 2025)

Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0 Indexed in PubMed



mdpi.com/si/217403

Journal of Personalized Medicine Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 jpm@mdpi.com

mdpi.com/journal/ jpm



Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0 Indexed in PubMed





About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. JPM publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). JPM is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).